Androgen receptor up-regulates insulin-like growth factor binding protein-5 (IGFBP-5) expression in a human prostate cancer xenograft.

The insulin-like growth factor (IGF) binding proteins (IGFBPs) are important modulators of IGF action in many tissues including human prostate. IGFBPs and the androgen receptor (AR) are expressed in CWR22, an androgen-dependent epithelial cell human CaP xenograft that retains biological characteristics of human CaPs, including regression following androgen withdrawal and recurrent growth of AR-containing cells in the absence of testicular androgens beginning several months after castration. Northern blot and in situ hybridization analyses demonstrated that IGFBP-5 is androgen-regulated in CWR22. IGFBP-5 messenger RNA (mRNA) decreased by 90% following castration of tumor-bearing mice compared with noncastrate androgen-stimulated mice. Testosterone treatment of CWR22 tumor-bearing mice 6 or 12 days after castration increased IGFBP-5 mRNA 10- to 12-fold. Levels of other IGFBP mRNAs did not change following androgen withdrawal and replacement. IGFBP-5 protein in tumor extracts bound 125I-labeled IGF-I in ligand blot assays and the amounts of IGFBP-5 measured by immunoblotting paralleled the levels of IGFBP-5 mRNA. Androgen-induced expression of IGFBP-5 was at a maximum level within 24 h after testosterone replacement, whereas the major increase in cell proliferation as measured by Ki-67 immunostaining occurred between 24-48 h. This time course suggested IGFBP-5 may be a mediator of androgen-induced growth of CWR22. In tumors that recurred several months following castration, IGFBP-5 mRNA and protein increased to levels that approached those in androgen-stimulated CWR22 tumors from noncastrate mice. IGFBP-5 immunohistochemical staining of prostate tissue specimens from patients was stronger in androgen-dependent and androgen-independent CaP than in areas of intraepithelial neoplasia (PIN) or benign prostatic hyperplasia (BPH). IGFBP-5 mRNA in these specimens was localized predominantly to stromal cells and IGFBP-5 protein to epithelial cell membranes.

[1]  P. Gumerlock,et al.  Human androgen receptor expression in prostate cancer following androgen ablation. , 1997, European urology.

[2]  M. Stampfer,et al.  Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. , 1998, Science.

[3]  Robert N. Holdefer,et al.  Quantitative immunocytochemistry using an image analyzer. I. Hardware evaluation, image processing, and data analysis , 1988, Journal of Neuroscience Methods.

[4]  R. Baserga,et al.  Inhibition of growth of prostatic cancer cell lines by peptide analogues of insulin-like growth factor 1. , 1993, Cancer research.

[5]  E. Froesch,et al.  1α,25‐Dihydroxyvitamin D3 increases IGF binding protein‐5 expression in cultured osteoblasts , 1996 .

[6]  G. Steiner,et al.  Differential expression of specific cytokeratin polypeptides in the basal and luminal epithelia of the human prostate , 1991, The Prostate.

[7]  D. Clemmons,et al.  Insulin-like growth factor-binding protein-5 is cleaved by physiological concentrations of thrombin. , 1998, Endocrinology.

[8]  N. Otsu.  A threshold selection method from gray level histograms , 1979 .

[9]  Jorma Isola,et al.  In vivo amplification of the androgen receptor gene and progression of human prostate cancer , 1995, Nature Genetics.

[10]  D. Andress,et al.  Regulation of Insulin-Like Growth Factor-Binding Protein-5 by Insulin-Like Growth Factor I and Interleukin-1α in Ovine Articular Chondrocytes. , 1998, Endocrinology.

[11]  B. Moats-Staats,et al.  Gene expression of insulin-like growth factors (IGFs), the type 1 IGF receptor, and IGF-binding proteins in dexamethasone-induced fetal growth retardation. , 1992, Endocrinology.

[12]  S. Schwartz,et al.  CWR22: androgen-dependent xenograft model derived from a primary human prostatic carcinoma. , 1994, Cancer research.

[13]  D. Tindall,et al.  Expression and androgenic regulation of human prostate-specific kallikreins. , 1995, Journal of andrology.

[14]  S. Mohan,et al.  Insulin-like growth factor-binding proteins in serum and other biological fluids: regulation and functions. , 1997, Endocrine reviews.

[15]  P. Ye,et al.  In vivo actions of insulin-like growth factor-I (IGF-I) on brain myelination: studies of IGF-I and IGF binding protein-1 (IGFBP-1) transgenic mice , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[16]  D. Clemmons,et al.  Transcription Factor AP-2 Regulates Human Insulin-like Growth Factor Binding Protein-5 Gene Expression (*) , 1995, The Journal of Biological Chemistry.

[17]  D. Peehl,et al.  Insulin-like growth factors (IGFs), IGF receptors, and IGF-binding proteins in primary cultures of prostate epithelial cells. , 1991, The Journal of clinical endocrinology and metabolism.

[18]  J. Ilan,et al.  Antisense RNA to the type I insulin-like growth factor receptor suppresses tumor growth and prevents invasion by rat prostate cancer cells in vivo. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[19]  H. Klocker,et al.  Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor and epidermal growth factor. , 1995, European urology.

[20]  S. Schwartz,et al.  CWR22: the first human prostate cancer xenograft with strongly androgen-dependent and relapsed strains both in vivo and in soft agar. , 1996, Cancer research.

[21]  N. Copeland,et al.  Organization, expression, and chromosomal location of the mouse insulin-like growth factor binding protein 5 gene. , 1994, Genomics.

[22]  J. Thrasher,et al.  Insulin-like growth factor-binding proteins (IGFBP)-4, -5, and -6 in the benign and malignant human prostate: IGFBP-5 messenger ribonucleic acid localization differs from IGFBP-5 protein localization. , 1996, The Journal of clinical endocrinology and metabolism.

[23]  D. Peehl,et al.  The IGF axis in the prostate. , 1994, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[24]  E. Froesch,et al.  1 alpha,25-dihydroxyvitamin D3 increases IGF binding protein-5 expression in cultured osteoblasts. , 1996, FEBS letters.

[25]  M. Serio,et al.  Insulin-like growth factor-I receptors in human hyperplastic prostate tissue: characterization, tissue localization, and their modulation by chronic treatment with a gonadotropin-releasing hormone analog. , 1991, The Journal of clinical endocrinology and metabolism.

[26]  S. Mohan,et al.  Insulin‐Like Growth Factor (IGF) System Components in Human Prostatic Cancer Cell‐Lines: LNCaP, DU145, and PC‐3 Cells , 1996, International journal of urology : official journal of the Japanese Urological Association.

[27]  Desok Kim,et al.  Androgen receptor expression in androgen-independent prostate cancer is associated with increased expression of androgen-regulated genes. , 1998, Cancer research.

[28]  K. Hamil,et al.  Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cells. , 1997, Molecular endocrinology.

[29]  Z. Shao,et al.  Regulation of insulin‐like growth factor‐binding‐protein‐1, 2, 3, 4, 5, and 6: Synthesis, secretion, and gene expression in estrogen receptor‐negative human breast carcinoma cells , 1993, Journal of cellular physiology.

[30]  D. Andress,et al.  Human osteoblast-derived insulin-like growth factor (IGF) binding protein-5 stimulates osteoblast mitogenesis and potentiates IGF action. , 1992, The Journal of biological chemistry.

[31]  L. Nazareth,et al.  Activation of the Human Androgen Receptor through a Protein Kinase A Signaling Pathway* , 1996, The Journal of Biological Chemistry.

[32]  V. Speights,et al.  Differential expression of insulin-like growth factor binding proteins in high versus low Gleason score prostate cancer. , 1998, The Journal of urology.

[33]  D. Peehl,et al.  Insulin-like growth factor axis abnormalities in prostatic stromal cells from patients with benign prostatic hyperplasia. , 1994, The Journal of clinical endocrinology and metabolism.

[34]  N. Ling,et al.  Identification of five different insulin-like growth factor binding proteins (IGFBPs) from adult rat serum and molecular cloning of a novel IGFBP-5 in rat and human. , 1991, The Journal of biological chemistry.

[35]  C. Larsson,et al.  Characterization of the chromosomal gene and promoter for human insulin-like growth factor binding protein-5. , 1994, The Journal of biological chemistry.

[36]  Schr,et al.  Androgen receptor status in localized and locally progressive hormone refractory human prostate cancer. , 1994, The American journal of pathology.

[37]  W. Rutter,et al.  Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. , 1979, Biochemistry.

[38]  D. Clemmons.  Insulin-like growth factor binding proteins and their role in controlling IGF actions. , 1997, Cytokine & growth factor reviews.

[39]  H. Klocker,et al.  Androgen receptor status of lymph node metastases from prostate cancer , 1996, The Prostate.

[40]  P. Wingo,et al.  An adjustment to the 1997 estimate for new prostate cancer cases , 1997, CA: a cancer journal for clinicians.

[41]  D. Clemmons,et al.  Identification of the forms of insulin-like growth factor-binding proteins produced by human fibroblasts and the mechanisms that regulate their secretion. , 1992, The Journal of biological chemistry.

[42]  T. Nam,et al.  Insulin-like growth factor binding protein-5 binds to plasminogen activator inhibitor-I. , 1997, Endocrinology.

[43]  P. Backeljauw,et al.  Synthesis and regulation of insulin-like growth factor binding protein-5 in FRTL-5 cells. , 1993, Endocrinology.

[44]  E. Froesch,et al.  Expression, effects, and fate of IGFBP-5 are different in normal and malignant osteoblastic cells. , 1995, Progress in growth factor research.

[45]  O. Jänne,et al.  Effects of mitogens on androgen receptor-mediated transactivation. , 1996, Endocrinology.